ABSTRACT: Osteonecrosis of the femoral head (ONFH) is a potentially devastating complication that occurs in up to 40% of young adults receiving chronic glucocorticoid (GC) therapy. Through a validated GC therapy rat model, we have previously shown that Wistar Kyoto (WK) rats exhibit a genetic susceptibility to GC-induced ONFH compared to Sasco Fischer (F344) rats. We have undertaken this study in order to investigate differences between these two strains for their bone parameters, alpha-2-macroglobulin (A2M) circulating levels and incidence of GC-induced osteonecrosis of the femoral head. WK and F344 rats were treated either with 1.5 mg/kg/day of prednisone or placebo for 6 months. Blood was taken every month. The femoral heads were harvested for histological examination to detect ONFH and analyzed with micro-computed tomography. After 3 months of GC-therapy, plasma A2M was elevated in treated rats only. GC-treated WK rats exhibited histological evidence of early ONFH through higher rates of cellular apoptosis and empty osteocyte lacunae in the subchondral bone compared to placebos and to F344 rats. Furthermore, micro-CT analysis exhibited femoral head collapse only in GC-treated WK rats. Interestingly, GC-treated F344 rats exhibited significant micro-CT changes, but such changes were less concentrated in the articular region and were accompanied histologically with increased marrow fat. These mCT and histological findings suggest that elevated A2M serum level is not predictive and suitable as an indicative biomarker for early GC-induced ONFH in rodents. Elevated A2M levels observed during GC treatment suggests that it plays role in the host reparative response to GC-associated effects.
BACKGROUND
Osteonecrosis of the femoral head (ONFH), previously known as avascular necrosis (AVN), is a serious complication that occurs in up to 40% of individuals taking high dose glucocorticoid (GC) therapy. 1 ONFH leads to progressive destruction of the hip joint, leading to premature osteoarthritis, and requirement for total hip arthroplasty (THA). Currently, late stage ONFH accounts for 10% of all THA procedures performed each year in North America. 2 Although THA is a reliable surgical treatment for osteoarthritis, its use in younger patients is associated with poor long-term outcomes due to implant failure and need for riskier revision surgery. 3 Early detection of ONFH prior to end-stage articular collapse is desirable in chronic GC patients as it permits surgical intervention through less morbid bone-preserving procedures which have the potential of delaying or even reversing disease progression. 4 This need is becoming more evident given the widening indications for GC use in the treatment of hematological malignancies, autoimmune, and respiratory diseases.
Pathogenic mechanisms that have been recently suggested for the development of GC-induced ONFH include mechanical blood vessel interruption (vascular hypothesis), 5 thrombotic occlusion, extravascular compression, 6 and specific genetic associations. [7] [8] [9] [10] We tested our "vascular hypothesis" for the pathogenesis of ONFH in a pilot study in which five inbred strains of rats received a continuous high dose of prednisone for 3 months. A high percentage of Wistar Kyoto (WK) rats developed histological and apoptotic changes compatible with osteonecrosis whereas the Sasco Fischer (F344) rats did not. 11 A subsequent controlled randomized study was conducted in which agematched WK and F344 rats were administered 1.5 mg/kg/day prednisone or placebo via sub-cutaneous pellets for 6 months. Microarray analysis of RNA isolated from the femoral head of GC-treated rats showed increased expression of alpha-2-macroglobulin (A2M) in the WK rats compared with F344 rats, which was confirmed using RT-PCR and immunohistochemistry. 12 A2M is a large, evolutionarily conserved protein that binds and inhibits a wide range of circulating proteinases. 13 It can activate different signaling pathways at the cellular level through its binding to its two main receptors: Low density lipoprotein receptorrelated protein (LRP1) 14 and glucose-regulated protein 78 kDa (GRP78). 15 In fact, it has been shown that A2M is involved in different biological processes such as diabetes, 16 cardiomyocyte hypertrophy in rats, 17 Alzheimer's disease 18 and coagulation regulation. 19 Major coagulation factors have been shown to be sequestered by A2M to be cleared from the circulation in the liver after binding to LRP1. 20 The central role played by A2M in hemostasis is also apparent from reports of its anti-coagulation activity, through binding to thrombin, and its capacity to limit fibrinolysis by sequestering fibrin. 21 Based on above, the primary outcome of this study was to investigate differences between WK and F344 rat strains for their bone parameters evaluated by histology and micro computed tomography. The secondary outcome was to test the hypothesis that A2M, due to its multiple hemostatic functions and our previous work, could be a component of ONFH physiopathology when induced by glucocorticoids.
METHODS

Rat Maintenance and Glucocorticoid Administration
All in vivo procedures were performed in compliance with a protocol approved by the McGill University Facility Animal Care Committee according to guidelines set by the Canadian Council on Animal Care. Eighteen WK and 18 F344 male rats aged 8-12 weeks (Charles River Laboratories, Quebec, Canada) were housed under standard conditions of 12 h dark/12 h light cycle, at a temperature of 20˚C, and humidity of 48%. During the 2-week acclimatization period and subsequent experimental period, a standard rodent diet and water were provided ad libitum. Slow-release pellets (Innovative Research of America, Sarasota, FL) measuring 1 Â 1 Â 0.5cm were inserted into anesthetized rats through a skin incision in the soft tissue at the base of the neck and the wound closed with a single suture as described previously. 11 Six rats were randomly chosen to receive placebo pellets and 12 rats received pellets calibrated to deliver 1.5 mg/kg/day of prednisone into the surrounding subcutaneous tissues for 90 days. This weightbased dose of prednisone was calculated in relation to the animal's average starting weight and has been previously shown to induce ONFH in WK rats. 11 A second pellet, also calibrated to deliver 1.5 mg/kg/day based on the animal's starting weight, was implanted in the same manner after 90 days providing 180 days of continuous GC or placebo treatment. The number of rats was higher in the GC-treated group in order to compensate for an expected higher loss of rats in that group following potential complications related to GC therapy such as diabetes, inflammation, or infection.
Serial In Vivo Measurements
All rats were weighed on entry into the animal facility and on a weekly basis thereafter. Glucose measurements were performed at 2 week intervals on blood drawn from the saphenous vein, using a portable glucometer (Contour Glucometer, Bayer). Once a month, 3 ml of whole blood was collected from each animal under general anesthesia through a sublingual method as previously described. 22 The serum was aliquoted and stored at À80˚C, with one aliquot dedicated to the measurement of A2M using a rat Alpha 2-Macroglobulin Enzyme Linked Immunoassay (ELISA) (Kamiya Biomedical Company, Seattle, WA) according to the manufacturer's instructions. A2M assays were performed by three individuals blinded to treatment allocation. Furthermore, in order to provide histological labelling of the bone mineralization front, intra-peritoneal injections of calcein (30 mg/kg, Sigma) and alizarin red (30 mg/kg, Sigma) were administered 7 days and 4 days prior to animal euthanasia. 23 Femur Harvest and Micro-Computed Tomographic Imaging At the conclusion of the 180 day experimental period, all rats were euthanized by brief exposure to isoflurane and exsanguination via cardiac puncture. Both femurs in each animal were dissected, with care to preserve the integrity of the femoral cartilage during hip disarticulation. The femurs were then osteotomized at the mid-diaphysis and the proximal portion fixed in 4% paraformaldehyde for 24 h, washed with sterile phosphate buffered saline (PBS) for 48 h and then stored in PBS at þ4˚C. mCT imaging was performed on all femurs using a Skyscan1172 instrument equipped with a 1.3 Mp camera (Skyscan, Kontich, Belgium) as described previously. 24 Serial 2D cross-sections were loaded into CTVox to generate volume-rendering models to visualize femoral head morphology. A custom program written in CTAn was used to segment the subchondral bone plate from epiphyseal trabecular bone in the femoral head for quantitative analyses of parameters as defined by Skyscan. Those defining the subchondral bone plate include bone volume/ tissue volume (BV/TV), bone mineral density (BMD), calibrated against a phantom rod of known BMD, and thickness of the bone plate across the top half of the femoral head. Damage to the femoral head was identified as a depression in the 3D axial view and confirmed on 2D coronal images. Subchondral collapse was defined as a visible concavity in the weight-bearing portion of the femoral head that was not in proximity or connected to the insertion of the ligamentum teres. The presence of subchondral collapse was also utilized to distinguish early ON (no collapse present) from late ON, mirroring the Ficat classification, 25 the most commonly utilized in clinical practice. 26 Parameters commonly described in the literature 27 were utilized to define trabecular bone architecture. These parameters included BV/TV; bone surface/tissue volume (BS/TV); trabecular (Tb) thickness (Th), separation (Sp), number (No), and pattern factor (Pf); trabecular connectivity and degree of anisotropy (DA). 27 1184 CARLI ET AL.
Histological Analysis of Femoral Heads
Following mCT analysis, the femoral heads were bisected in the coronal plane using a Diamond saw (Leica, St-Joseph, MI). One half was embedded at low temperature in polymethylmethacrylate (PMMA, Fisher Scientific, Ontario, Canada) as described previously. 28 Specimens were dehydrated in alcohol from 70% to 100%, before embedding in resin. Five or ten micron-thick sections were cut on a Leica RM2265 rotary microtome (Leica Microsystems, Richmond Hill, Canada). The 10 micron-thick sections were left unstained for visualization of the fluorescent calcein and Alizarin red labels administered in vivo in the final week of the experiment. Serial sections were stained with Von Kossa/ Toluidine Blue, to distinguish mineralized from un-mineralized tissue, with alkaline phosphatase (ALP) to identify osteoblasts and hypertrophic chondrocytes or with tartrateresistant acid phosphatase (TRAP) to identify osteoclasts as previously described. 31 The second half of the femoral head was decalcified in EDTA, embedded in paraffin and serial five micron-thick sections cut and stained with hematoxylin & eosin (H&E) to determine the presence of empty osteocyte lacunae and other general findings of ONFH. Sections were also stained with Safranin O/Fast green to identify proteoglycans, Picrosirius red to identify type I collagen, or for TUNEL labelling of apoptotic nuclei using TUNEL kit (Roche Diagnostics, Laval, QC, Canada) as described previously. 32 Without knowledge of the treatment groups, two experienced board-certified pathologists (AN, RPM) scored the fivemicron-thick sections independently on a scale of 0-3 for the presence of marrow fat and marrow necrosis, the number of empty osteocyte lacunae per high-powered field (hpf) and the number of TUNEL-positive apoptotic cells per hpf. The grading score, when applicable was as follows: Grade 0 for no positive cells per hpf; grade 1 for <5 positive cells per hpf; grade 2 for 5-10 positive cells per hpf; grade 3 for >10 positive cells per hpf. When there was discordance in scoring, the two observers met to achieve a consensus score. Osteonecrosis was diagnosed when the combination of empty osteocyte lacunae and apoptosis of surrounding osteocytes were diffusely present. [29] [30] [31] This histological description coupled with the lack of radiographic evidence of subchondral collapse was collectively defined as early ON.
Statistical Analysis
All statistical tests were performed using SPSS Statistical Software version 19.0 (SPSS Inc., Chicago, IL). Data were assessed for normalcy using the Shapiro-Wilk test. Analysis of variance (ANOVA) for repeated measures was used to examine change in body weight and serum glucose, with treatment using placebo or glucocorticoids tested as independent factors. Comparison between GC and placebo groups for mCT bone morphometric indices were performed using a Mann-Whitney U test. A Kruskal-Wallis test was conducted to evaluate differences in serum A2M levels among placebotreated animals that developed ONFH, GC-treated animals that developed ONFH, and animals that did not develop ONFH. Mean histological grading of diagnostic ONFH criteria was compared among GC and placebo animals using a Kruskal-Wallis test or two-way student's t-test when indicated. Post-hoc tests to evaluate pairwise differences among comparisons of more than two groups were performed utilizing a Bonferroni adjustment to control for Type 1 error. For all pair-wise comparisons, differences were considered significant at p-values less than 0.05.
RESULTS
Weight, Glucose, and Serum A2M Changes
The body weight of all rats increased across the experimental period. The mean body weight at 6 months in the placebo and the GC-treated group was 394 AE 42 and 354 AE 14 g for F344 rats and 747 AE 35 and 709 AE 78 g for WK rats, respectively (Table 1) . No statistically significant differences were found in percent weight gain between placebo and GC-treated groups of F344 (p ¼ 0.102) or WK (p ¼ 0.867) rats. Due to the increase in weight, weight-based GC dosing decreased in the second half of the experiment from 1.5 mg/kg/day to 1.07 mg/kg/day in WK rats, and from 1.5 mg/kg/day to 1.29 mg/kg/day in F344 rats. Serum glucose, a potential indicator of GC-induced insulin resistance, remained close to normal limits for all animals over time, with no difference between placebo and GC-treated groups of F344 (p ¼ 0.318) or WK (p ¼ 0.673) rats (Table 1) .
In contrast, serum A2M levels rose only in GC-treated rats. No increased A2M levels were observed in any of the control animals ( Table 1) . A Kruskal-Wallis test revealed that the GC-induced elevation in A2M at 3 months was statistically significant in WK rats (
A2M levels in all GC-treated F344 rats dropped to the baseline level by 4 months whereas levels generally remained elevated in WK rats at 6 months. Also of note, A2M levels were found to be profoundly higher in rats having a heavier weight (WK rats being twice as heavy as F344 rats).
Semi-Quantitative Histological Analyses of Femoral Heads
The identification of osteocyte apoptosis and empty osteocyte lacunae were the two criteria specified for a diagnosis of GC-induced ONFH on histological sections from the affected area. Additional aspects including marrow necrosis, marrow fat, articular collagen damage, and proteoglycan loss were also evaluated. All of the above histologic features were scored without knowledge of treatments groups on a scale of 0-3 by the two pathologists. The mean scores and standard deviations for each feature are provided in Table 2 .
In both F344 (Fig. 1A and B) and WK ( Fig. 1C and D) rats, GC treatment induced an increase apoptosis of osteochondrocyte at the articular surface ( Fig. 1B1  and D1 ), bone marrow cells as well as osteocyte in metaphyseal bone and lining the marrow cavities ( Fig. 1B2 and D2 ) when compared with placebotreated F344 (Fig. 1A-A2 ) and WK (Fig. 1C-C2 ) rats. Statistical analysis revealed that this increase was significant only in WK (t ¼ 2.196; p ¼ 0.036) and not F344 rats (t ¼ 0.856; p ¼ 0.399). For sections stained with H&E, an increase in the number of empty osteocyte lacunae were observed in GC-treated rats (Fig. 2I-L ) compared to placebo ( Fig. 2A-D) . Although, no overall statistical significance was noted for GC-treated WK (Z ¼ 0.867; p ¼ 0.386) and F344 rats (Z ¼ 0.076; p ¼ 0.939), 2 or more empty lacunae per hpf OSTEONECROSIS IN SUBSTRAINS OF RATS were noted for 6 of 11 GC-treated WK rats compared to 0-1 in all placebo rats and 0-1 in all GC-treated F344 rats.
With regard to general features of ONFH, the presence of marrow necrosis was observed in some treated rats (Fig. 2E-H (Table 2) .
Sections stained with Picrosirius Red (data not shown) revealed mild GC-induced damage to collagen at the articular surface in both rat strains. Comparison of Safranin O staining of proteoglycan in the femoral heads of representative F344 rats (Fig. 3A and  B) showed little leaching from the articular surface in GC-treated rats compared with controls (Z ¼ 0.996; p ¼ 0.319). In contrast, GC-treated WK rats exhibited areas of articular surface (Fig. 3D ) that were devoid of proteoglycan compared to placebo animals (Fig. 3C ) despite the overall differences not being statistically significant (Z ¼ 0.739; p ¼ 0.460). Damage to the articular cartilage in the WK rats was accompanied by progression of the tidemark towards the articular surface. For comparison, remnants of growth plate cartilage are shown (Fig. 3A3-D3 ).
Quantitative Micro-Computed Tomographic Analyses Protocols adapted from those developed for high resolution quantitative mCT analyses of murine bone 33 were used to analyze the micro-architecture and composition of femoral head bone. It is important to stress that computed-tomography (CT) is not a modality utilized clinically to diagnose ONFH. To date, no description of the relationship between histological changes in ONFH and mCT changes in rodents exist in the literature. 
OSTEONECROSIS IN SUBSTRAINS OF RATS
Representative 3D reconstructions are shown in the axial (Fig. 4A-D) and coronal ( Fig. 4A1-D1 ) planes, with corresponding 2D coronal images (Fig. 4A2-D2 ) and histological sections stained with Von Kossa/Toluidine blue ( Fig. 4E-H) . When assessing samples for criteria relating to the collapse of the subchondral bone plate using microCT, a significant difference was noted between rat strains. As such, evaluation by microCT showed that 6 of the 11 GC-treated (Fig. 4D arrowhead, Fig. 4D1 ) WK rats met the criteria for subchondral collapse compared to 0 of the 12 GC-treated F344 rats (x 2 ¼ 8.250; p ¼ 0.0041), and no evidence of collapse in any placebo-treated animals.
Quantitative mCT analysis was performed with a custom program as previously described 29 and the results are demonstrated in Table 3 . When comparing each rat strain individually, GC treatment resulted in a significant decrease in both subchondral and trabecular bone volume (p < 0.05), as well as bone plate thickness (p < 0.05) in F344 rats. Meanwhile in WK rats, bone volume was decreased in the subchondral area only (p < 0.05) and not in the trabecular bone underneath. When comparing the two rat strains to each other, F344 rats exhibited lower bone volume, bone mineral density and thinner trabeculae (TrTh) compared with WK rats (p < .01) as well as an increased bone surface (BS/TV) and decreased anisotropy (p < 0.05). Overall, GC-treated F344 rats exhibited a more severe decrease in bone integrity compared to WK rats, yet this decrease had a widespread effect on bone both adjacent to the articular surface and beneath the growth plate. Although WK rats exhibited less severe quantitative decreases, such decreases were focally affected with GC treatment only in the subchondral area. Furthermore, WK rats were the only strain to exhibit articular surface collapse. 
Histological Analyses of Bone Cell Function
Three dimensional loss of trabecular connectivity and an increase in anisotropy evident on mCT analyses have been implicated in the predisposition to fracture of osteoporotic bone. 27 Additional histologic analyses of anabolic and catabolic cell function were therefore utilized to explore the micro-architectural changes visible at the tissue level. Five micron-thick sections of undecalcified femoral head bone from representative F344 rats treated with placebo (Fig. 5A , E, and I) or GC (Fig. 5B, F , and J) and WK rats treated with placebo (Fig. 5C , G, and K) or GC (Fig. 5D , H, and L) were stained for ALP activity in osteoblasts (Fig. 5A-D) , left unstained (Fig. 5E-H) , or stained for TRAP activity in osteoclasts (Fig. 5I-L) . ALP was seen at the junction between cartilage and bone ( Fig. 5A1-D1 arrows) . Dynamic labeling of bone-forming surfaces with fluorescent dyes revealed robust osteoblast activity in F344 rats, treated with either placebo (Fig. 5E) or GC (Fig. 5F ), but little labeling of placebo-treated (Fig. 5G) or GC-treated (Fig. 5H ) WK rats. TRAP-positive osteoclasts (Fig. 5I1-L1 asterisk) were seen at the junction between subchondral and trabecular bone, and in bone beneath the remnants of the growth plates.
DISCUSSION
Previous in vitro work from our laboratory supports a "vascular" hypothesis for the pathogenesis of nontraumatic osteonecrosis. These studies suggested that 
OSTEONECROSIS IN SUBSTRAINS OF RATS
resultant micro-vascular damage at the endothelial cell level leads to an interruption in regional blood flow and could be the initiating event in the development of ONFH. 32 An intermediary in endothelial injury could be a potential biomarker for GC-induced ONFH. Subsequent in vivo work revealed a "genetic" susceptibility to ONFH in WK rats that was absent in F344 rats. 11 Additionally, gene profiling of femoral head bone from GC-treated rats showed an overexpression of A2M in affected rats. 12 The current study was undertaken to identify if differences in bone parameters, and A2M circulation levels are responsible for the difference in osteonecrosis incidence in two different strains of rats known to be distinct in their susceptibility to the development of GC-induced ONFH. The first strain was chosen due to its resistance to the GC end-organ effects and GC-induced ONFH (F344 rats), 11 and it was compared to a second, more susceptible strain (WK rats). Secondarily, we wanted to: (i) determine if a significant difference existed in bone parameters evaluated by mCT and histology which can explain the genetic susceptibility differences towards ONFH and (ii) explore any association between the A2M functions and the pathogenesis of GC-induced ONFH.
Several studies have suggested different criteria for the diagnosis of ONFH in rats. Based on our previous experiments and on studies of other groups, 1, 11, [33] [34] [35] we used a histological diagnosis of GC-induced ONFH that pertains solely to evidence of osteocyte death through the presence of empty osteocyte lacunae and positive osteocyte apoptotic staining (terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL]). 33, 36, 37 In addition to these criteria, histological findings generally described in ONFH such as markers of bone formation and turnover, as well as high-resolution imaging including mCT qualitative and quantitative data, are also provided to generate a broader comparison of GC-treated animals versus controls within and among two rat strains.
In the current study, histological analysis of the femoral heads of WK rats demonstrated degenerative changes focally in articular cartilage and bone that were reminiscent of the later stages of human ONFH, compared to F344 rats. Such a distinction was also visible on mCT, with WK rats exhibiting femoral head collapse and quantifiable reductions of subchondral density only, while F344 rats exhibited a generalized reduction in bone density without any articular disturbance. Such a strain-specific distinction could indicate that the effect of GCs on the WK femoral heads is concentrated subchondrally and therefore affects the articular surface more significantly. The loss of proteoglycan and progression of mineralized tissue to the articular surface are in fact characteristic signs of osteoarthritis in animal and human species. [38] [39] [40] Another interesting bone-related phenotype in the WK rats was the tendency of a greater number of empty osteocyte lacunae in both the control and GC-treated groups compared with F344 rats, although these results did not reach statistical significance. It has been reported that the number of osteocytes decrease by >50% from young adult to aged humans, leaving empty lacunae that are associated with decreased structural integrity of bone and increased bone fragility. 41 In the current study, apoptosis was significantly increased in WK rats treated with GCs. The discrepancy could reflect differences in the capacity to regenerate osteogenic cells or an indirect effect caused by blockage of the microcirculation.
Identification of elevated expression of A2M in RNA isolated from the femoral heads of GC-treated WK rats with clinical ONFH in our previous study 12 suggests that a concomitant increase in the translation product could occlude or damage capillaries in bone. This hypothesis is supported by data from others documenting a steroid-induced increase in A2M production by liver cells, the presence of A2M covering the luminal surface of endothelial cells in human arteries and veins, the involvement of A2M in the regulation of hemostasis 42 and by our own unpublished data showing A2M upregulation in HUVECs exposed to dexamethasone. In the current study, A2M was significantly elevated, reaching a peak at 3 months in the peripheral circulation of GC-treated WK and F344 rats, but not in controls. Although A2M levels did rise in both rat strains studied, the median level of A2M was higher in WK compared with F344 rats and remained elevated above baseline at 6 months. The WK rats demonstrated a more robust and prolonged elevation in A2M in response to GC in comparison to the F344 rats. However, based on current histological and bone cell function findings, which show mainly no 
significant difference between GC-treated rats compared to placebo-treated rats (except for apoptosis), A2M can therefore not be considered a biomarker of early osteonecrosis. It seems however that an increased A2M serum level is correlated with prolonged GC treatment only, which might damage not only bone but several other tissues and organs. The major source of increased plasma A2M in the current study was most probably the liver 43 which surely reacts to prolonged GC treatment. However, we cannot exclude that de novo synthesis could also have increased locally in MSC. 44 In further support of this, A2M, complexed with its receptor LRP1 45 or aggregated in plaques as seen in atherosclerosis, renal disease, or dementia 46 could lead to ischemia. Ischemic damage to bone marrow can trigger accumulation of reactive oxygen species that subsequently could promote apoptosis of osteocytes which was observed significantly in GC-treated WK rats. Although a greater degree of bone marrow changes were noted in F344 rats, there was less evidence of cellular insult at the articular level as reflected by no significant increases in positive TUNEL staining or sections with multiple empty osteocyte lacunae. In contrast, GC-treated WK rats showed little bone marrow necrosis and marrow fat, but instead possessed a significantly elevated level of apoptotic cells at the articular level that were often accompanied (although not statistically significant) with numerous empty osteocyte lacunae and compromised bone architecture on mCT, suggestive of an evolution towards a more advanced stage of ONFH.
CONCLUSION
Findings from the current study demonstrate in particular solid and convincing mCT data with respect to differences in bone parameters between the two rat strains studied rather than differences between placebo and GC-treated groups. This is very obvious for the WK strain where almost no statistically significant differences between the placebo and the GC-treated groups were detected, whereas for the F344 strain, a decline in subchondral bone volume, trabecular thickness, and bone anisotropy were discovered. To our knowledge, this is the first study using mCT as an adjunct to histology for the diagnosis of GC-induced ONFH in rodents. Our results suggest that an elevated A2M serum level is not predictive nor suitable as an indicative biomarker for early GC-induced ONFH in rodents. On the other hand, elevated A2M is correlated to GC treatment and may represent a form of reparative response to GCassociated damage of bone as well as several other tissues and organs.
Future experiments investigating the effect of increased circulating A2M levels and femoral head vascularity as well as the effect of GC administration on an A2M knockout animal are required to further define the role that A2M plays in the pathogenesis of GC-induced ONFH. Prospective translational investigations into changes in serum A2M levels in humans are already underway to determine the role of A2M in the physiopathology of GC-mediated ONFH and to further characterize how differences in circulating levels of A2M between species affects the onset or progression of this debilitating complication following chronic glucocorticoid administration.
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